The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.
A. S. Pickard
Employment or Leadership Position - EuroQoL Group
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Analysis Group
D. Cella
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Analysis Group
Research Funding - GlaxoSmithKline; Novartis; Pfizer
M. S. Duh
Research Funding - GlaxoSmithKline
A. Guerin
Research Funding - GlaxoSmithKline
N. Mishagina
Research Funding - GlaxoSmithKline
L. AntrĂ s
Research Funding - GlaxoSmithKline
M. Neary
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. Hodge
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Sternberg
Honoraria - Analysis Group; Bayer; GlaxoSmithKline; Novartis; Pfizer